← Leaderboards
Patricia S Braly
Tulane University Of Louisiana
$22,399
Attributed
$22,399
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$22,399 · 5
By mechanism
M01$22,399 · 5
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Jay K Kolls$45,526,904
- Paul O Schwarzenberger$3,319,899
- Ellen L Zakris$642,522
- Yi-Ping Li$19,044,938
- William McKinnon$49,515
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyClinical ResearchCis Platinum CompoundPaclitaxelCombination ChemotherapyDoxorubicinOvary NeoplasmsUterus NeoplasmsSquamous Cell CarcinomaTopotecanFemaleCervix NeoplasmsColony Stimulating FactorCombination Cancer TherapyDrug Administration Rate /DurationDrug Adverse EffectDrug Screening /EvaluationAntineoplasticsNeoplasm /Cancer ImmunotherapyPeritoneum Neoplasm
Grant awards (10)
PACLITAXEL/CISPLATIN IN OVARY/PERITONEUM CARCINOMA$0
M01 · FY2001 · RR
GOG 169:CISPLATIN VS CISPLATIN + PACLITAXEL IN SQUAMOUS CELL CARCINOM$0
M01 · FY2001 · RR
SEQU3049:STUDY OF DOXIL VS TOPOTECAN HCL IN PATIENTS W/ OVARIAN CANCE$0
M01 · FY2001 · RR
DOXORUBICIN + CISPLATIN IN ENDOMETRIAL CARCINOMA$0
M01 · FY2001 · RR
DOXORUBICIN, CISPLATIN, PACLITAXEL, G-CSF IN UTERINE CA$0
M01 · FY2001 · RR
SEQU3049:STUDY OF DOXIL VS TOPOTECAN HCL IN PATIENTS W/ OVARIAN CANCE$11,219
M01 · FY2000 · RR
GOG 169:CISPLATIN VS CISPLATIN + PACLITAXEL IN SQUAMOUS CELL CARCINOM$11,180
M01 · FY2000 · RR
DOXORUBICIN + CISPLATIN IN ENDOMETRIAL CARCINOMA$0
M01 · FY2000 · RR
DOXORUBICIN, CISPLATIN, PACLITAXEL, G-CSF IN UTERINE CA$0
M01 · FY2000 · RR
PACLITAXEL/CISPLATIN IN OVARY/PERITONEUM CARCINOMA$0
M01 · FY2000 · RR